Merck inks $1.9B Pandion takeover to square up against Amgen, Lilly and Roche

Retrieved on: 2021-02-25 13:52:30

Tags for this article:

Click the tags to see associated articles and topics

Merck inks $1.9B Pandion takeover to square up against Amgen, Lilly and Roche. View article details on hiswai:

Excerpt

Amgen's efavaleukin alfa —formerly known as AMG592—and Roche's RG7835 are in phase 1 development. Data on PT101 and its rivals suggest ...

Article found on: www.fiercebiotech.com